Signal
In a reminder of the money still available for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 ...
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-01-22 18:00 UTCUpdated 2026-01-22 19:00 UTC
rss
biopharma_dive
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.
Score total
1.01
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Investors load Corxel with $287M for a ‘differentiated’ obesity pill
BioPharma Dive (Latest) · biopharmadive.com · 2026-01-22 19:00 UTC
In a reminder of the money still available for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in series D funds to bankroll phase 2 studies of its oral ...
Fierce Biotech (All) · fiercebiotech.com · 2026-01-22 18:00 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (Latest) (1)
- Fierce Biotech (All) (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)